Group 1 - Changyuan Power reported a power generation of 2.742 billion kWh in September, a year-on-year decrease of 41.88% [1] - The cumulative power generation from January to September was 27.332 billion kWh, down 8.24% year-on-year [1] - Huanyu Electronics achieved a consolidated revenue of 5.96 billion yuan in September, a year-on-year increase of 0.1% [1][2] Group 2 - Zhonghuan Environmental announced a change in controlling shareholder, with 27.5% of shares being transferred for a total consideration of 598 million yuan [2] - *ST Songfa's subsidiary signed contracts for the construction of 6 VLCCs, with a total contract value of approximately 600-900 million USD [1][3] - Suzhou Xinchen Technology's subsidiary plans to acquire 55% of Kunyu Lancheng for 74.25 million yuan [3] Group 3 - Guiguan Power reported a cumulative power generation of 31.848 billion kWh for the first three quarters, a year-on-year increase of 14.89% [4] - Jincheng Pharmaceutical's subsidiary received approval for the market launch of a raw material drug [4] - Shandong Steel expects a net profit of approximately 140 million yuan for the first three quarters, an increase of about 21.96 million yuan year-on-year [4][5] Group 4 - Xiangjia Co. reported sales revenue of 96.6186 million yuan from live poultry in September, with a sales price of 12.10 yuan/kg [6] - Aonong Bio's pig sales volume in September increased by 12.2% year-on-year, with a total of 164,400 pigs sold [7] - Mingtai Aluminum's aluminum plate and foil sales reached 1.1747 million tons in the first three quarters [8] Group 5 - Guangzhou Port expects to complete a container throughput of 2.051 million TEUs in September, a year-on-year decrease of 0.8% [11] - Jiangsu Sop plans to conduct a month-long maintenance on several production units starting October 10 [12] - Baike Bio received approval for a clinical trial of a combined vaccine for infants [13] Group 6 - Yutong Bus reported a 25.55% year-on-year increase in bus sales in September, totaling 4,756 units [16] - Shanghai Rural Commercial Bank's vice chairman and president's qualifications were approved [19] - Huayu Pharmaceutical's product received market approval in four countries [20] Group 7 - Longan Automobile reported a 24.92% year-on-year increase in vehicle sales in September, totaling 266,300 units [38] - Chip Origin expects a third-quarter revenue of 1.284 billion yuan, a year-on-year increase of 78.77% [39] - Bomaike signed a contract for an offshore floating production storage and offloading vessel project, with a contract value of approximately 190-240 million USD [40]

2025 年第三季度可转换公司债券转股情况公告 | | | 债券代码：127017 债券简称：万青转债 债券代码：524330 债券简称：25江泥01 江西万年青水泥股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 股票代码：000789；股票简称：万年青 债券代码：127017；债券简称：万青转债 转股价格：人民币 8.53 元/股 转股时间：2020 年 12 月 9 日至 2026 年 6 月 2 日 根据《深圳证券交易所股票上市规则》《深圳证券交易所上市公 司自律监管指引第15号——可转换公司债券》的有关规定，江西万年 青水泥股份有限公司（以下简称"公司"）现将2025年第三季度可 转换公司债券（以下简称"可转债"或"万青转债"）转股及公司股 份变动情况公告如下： 一、可转债发行上市情况 2024年4月19日，公司召开第九届董事会第十三次临时会议审议 通过了《关于向下修正"万青转债"转股价格的议案》，根据《募集说 明书》等相关规定及公司2023年年度股东大会的授权，董事会决定 将"万青转债"的转股价格向下修正为8.76元/股，修 ...

| 证券代码：000789 | 证券简称：万年青 公告编号：2025-70 | | --- | --- | | 债券代码：127017 | 债券简称：万青转债 | | 债券代码：524330 | 债券简称：25 江泥 01 | 委员会对提名人选资格审查通过并提名，公司董事会同意聘任章魁峰 先生为公司副总经理，任期自本次董事会审议通过之日至第十届董事 会任期届满为止。章魁峰先生的简历详见附件。 一、高级管理人员离任情况 近日，江西万年青水泥股份有限公司（以下简称"公司"）董事 会收到公司副总经理孙林先生的书面辞职报告。因工作调动原因，孙 林先生申请辞去公司副总经理职务。 孙林先生原定的任职期间为2024年9月20日至2027年9月19日，根 据《公司法》《公司章程》等有关规定，孙林先生的辞职报告自送达 公司董事会之日起生效。孙林先生辞去上述职务后，将继续在部分控 股子公司担任董事职务。截止本公告披露日，孙林先生未持有公司股 份。孙林先生为公司2022年股票期权激励计划的激励对象，其持有已 获授但尚未行权股票期权公司将依据《2022年股票期权激励计划》的 相关规定进行处理。 孙林先生在担任公司副总经理期间恪尽职守 ...

| 证券代码：000789 | 证券简称：万年青 | 公告编号：2025-71 | | --- | --- | --- | | 债券代码：127017 | 债券简称：万青转债 | | | 债券代码：524330 | 债券简称：25 江泥 01 | | 江西万年青水泥股份有限公司 第十届监事会第六次临时会议决议公告 由江西于都南方万年青水泥有限公司吸收合并江西赣州南方万年青水泥有限公司， 由江西瑞金万年青水泥有限责任公司吸收合并江西石城南方万年青水泥有限公司，由 江西乐平万年青水泥有限公司吸收合并乐平万年青商砼有限公司，由九江广德新型材 料有限公司吸收合并九江万年青商砼有限公司，依法注销南昌万年青水泥有限责任公 司，依法注销江西于都万年青聚通环保有限公司。 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 江西万年青水泥股份有限公司（以下简称公司）第十届监事会第六次临时会议通 知于 2025 年 9 月 27 日以电子邮件和公司网上办公系统方式发出，会议于 2025 年 9 月 30 日以通讯方式召开。 会议应出席监事 5 名，实际出席监事 ...

| 证券代码：000789 | 证券简称：万年青 公告编号：2025-69 | | --- | --- | | 债券代码：127017 | 债券简称：万青转债 | | 债券代码：524330 | 债券简称：25 江泥 01 | 江西万年青水泥股份有限公司 第十届董事会第九次临时会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 江西万年青水泥股份有限公司（以下简称"公司"）第十届董事会第九次临时会议 通知于 2025 年 9 月 27 日以电子邮件和公司网上办公系统方式发出，会议于 2025 年 9 月 30 日以通讯方式召开。 本次会议审议通过了以下议案： （一）审议通过了《关于聘任公司高级管理人员的议案》 近日，公司董事会收到公司副总经理孙林先生的书面辞职报告。因工作调动原因， 孙林先生申请辞去公司副总经理职务。 根据公司总经理的推荐，由公司提名委员会提名，董事会同意聘任章魁峰先生为 公司副总经理，任期自本次董事会审议通过之日起至第十届董事会届满为止。 具体内容详见公司同日披露的《关于公司副总经理辞职及新聘高级管理人员的公 ...

截至发稿，万年青市值为46亿元。 每经头条（nbdtoutiao）——上海一城中村试水房票安置，村民组团买房，有楼盘已预收约70张房票 （记者 王晓波） 每经AI快讯，万年青（SZ 000789，收盘价：5.8元）10月8日晚间发布公告称，因工作调动原因，孙林 先生申请辞去公司副总经理职务。孙林先生辞去上述职务后，将继续在部分控股子公司担任董事职务。 经公司董事会提名委员会对提名人选资格审查通过并提名，公司董事会同意聘任章魁峰先生为公司副总 经理。 2025年1至6月份，万年青的营业收入构成为：水泥制造业占比68.44%，混凝土占比22.71%，骨料占比 5.43%，其他行业占比2.25%，贸易占比1.17%。 ...

Group 1 - The core point of the article highlights that Jiangxi Wannianqing Cement Co., Ltd., a company related to CITIC Securities, has announced a tender for a key technology research project on low-carbon alternative fuel application, with a budget of 34.536 million yuan [1] - The project is specifically for the civil engineering and steel structure works of the Wannian Cement Plant [1] - CITIC Securities holds a 0.60% stake in Jiangxi Wannianqing Cement Co., Ltd. according to the equity penetration data [1]

Group 1 - The core point of the article is that Shantou Yinkang Enterprise Management Consulting Partnership (Limited Partnership) has reduced its stake in Guangdong Wan Nian Qing by selling 1.8841 million shares, which represents 1.1775625% of the company's total share capital [1] - After this equity change, the controlling shareholder, Guangdong Jinou Health Technology Co., Ltd., along with its concerted parties, holds a total of 87.9774 million shares, accounting for 54.9858875% of the company's total share capital [1]

Group 1 - The core viewpoint of the article is that the cement prices in the region where the company operates have increased by approximately 20 to 30 yuan per ton since September [1]

Core Viewpoint - The company is committed to the inheritance and innovation of traditional Chinese medicine, actively advancing the research and development of innovative traditional Chinese medicine products and the secondary development of key varieties [1] Group 1: R&D Initiatives - The company is focusing on the modernization of classic formulas in the chronic disease field [1] - The company is exploring partnerships with research institutions in the classic formula area to promote project collaboration [1] Group 2: Strategic Partnerships - The company has established a strategic cooperation with Shantou University Medical College to jointly conduct new drug development and related basic and clinical research [1] - This partnership aims to accelerate the progress of innovative traditional Chinese medicine research and development [1]